Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.42 |
| ▸ | FNTB | P49356 | 4/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706104 | 1.00 | FNTA (0.42) | FNTAFNTBPGGT1BCYP51A1CYP3A4 | |
| SCHEMBL8360606 | 0.89 | FNTA (0.52) | FNTAFNTB | |
| SCHEMBL7703301 | 0.89 | FNTA (0.52) | FNTAFNTB | |
| SCHEMBL7703293 | 0.89 | FNTA (0.52) | FNTAFNTB | |
| SCHEMBL7706098 | 0.88 | FNTA (0.42) | FNTAFNTBPGGT1BCYP51A1CYP3A4 | |
| SCHEMBL7706093 | 0.88 | FNTA (0.42) | FNTAFNTBPGGT1BCYP51A1CYP3A4 | |
| SCHEMBL7706086 | 0.87 | FNTA (0.55) | FNTAFNTB | |
| SCHEMBL7706082 | 0.87 | FNTA (0.55) | FNTAFNTB | |
| SCHEMBL7706097 | 0.86 | FNTA (0.43) | FNTAFNTBPGGT1BCYP51A1CYP3A4 | |
| SCHEMBL7706092 | 0.86 | FNTA (0.43) | FNTAFNTBPGGT1BCYP51A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | claimed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |